<p>Corvus Pharmaceuticals, Inc.（纳斯达克代码：CRVS - 获取免费报告）的股票在覆盖该股票的五家经纪公司中被评为 “适度买入”，MarketBeat Ratings 报告称。一位股票研究分析师给予该股票卖出评级，四位分析师给予该公司买入评级。在过去一年中，给予该股票评级的经纪公司平均一年目标价为 13.75 美元。</p>
<p>获取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
<p>几位分析师最近对 CRVS 股票发布了报告。华尔街禅在 8 月 9 日的报告中将 Corvus Pharmaceuticals 的股票评级从 “卖出” 上调至 “持有”。巴克莱在周一的报告中开始覆盖 Corvus Pharmaceuticals 的股票。他们对该股票设定了 “增持” 评级和 16.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Corvus Pharmaceuticals 股票的 “卖出（d-）” 评级。</p>
<p><strong>阅读我们关于 CRVS 的最新报告</strong></p>
<h2>Corvus Pharmaceuticals 股票下跌 4.4%</h2>
<p>CRVS 股票周一开盘价为 6.93 美元。该公司的市值为 5.1635 亿美元，市盈率为 -6.86，贝塔值为 0.57。该公司的 50 日简单移动平均线为 5.83 美元，200 日简单移动平均线为 4.49 美元。Corvus Pharmaceuticals 的 12 个月低点为 2.54 美元，12 个月高点为 10.00 美元。</p>
<p>Corvus Pharmaceuticals（纳斯达克代码：CRVS - 获取免费报告）最近一次公布财报是在 8 月 7 日。该公司报告本季度每股收益为（0.10）美元，超出市场共识预期的（0.13）美元 0.03 美元。股票研究分析师预测 Corvus Pharmaceuticals 本年度每股收益将为 -0.63。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Shelton Wealth Management LLC 在第三季度收购了 Corvus Pharmaceuticals 的新头寸，价值约 101,000 美元。中国泛海资产管理有限公司在第二季度将其在 Corvus Pharmaceuticals 的持股增加了 20.2%。中国泛海资产管理有限公司现在拥有 15,488 股该公司的股票，价值 62,000 美元，此前在此期间又购买了 2,599 股。Squarepoint Ops LLC 在第二季度将其在 Corvus Pharmaceuticals 的持股增加了 37.0%。Squarepoint Ops LLC 现在拥有 138,462 股该公司的股票，价值 554,000 美元，此前在此期间又购买了 37,430 股。Sender Co &amp; Partners Inc. 在第二季度收购了 Corvus Pharmaceuticals 的新头寸，价值约 52,000 美元。最后，Perceptive Advisors LLC 在第二季度收购了 Corvus Pharmaceuticals 的新头寸，价值约 5,754,000 美元。46.64% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Corvus Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Corvus Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，专注于开发和商业化免疫调节剂产品候选药物，以治疗实体癌症、T 细胞淋巴瘤、自身免疫性疾病、过敏性疾病和传染病。其主要产品候选药物是 soquelitinib（CPI-818），这是一种选择性共价抑制剂，针对白细胞介素 2 诱导的 T 细胞激酶（ITK），目前正在进行多中心的 1/1b 期临床试验，以治疗外周 T 细胞淋巴瘤、实体肿瘤和特应性皮炎。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Corvus Pharmaceuticals</li>
<li>5 只适合股息增长投资者的折扣机会</li>
<li>Reddit-ChatGPT 的爱情故事结束了吗？</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>3 只铜股票准备在下一个金属超级周期中大放异彩</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>Microsoft 365 Premium 标志着 AI 货币化的下一个阶段</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
<p>在你考虑投资 Corvus Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐，现在就买入，以便在更广泛的市场注意到之前... 而 Corvus Pharmaceuticals 并不在名单上。</p>
<p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

Corvus制药

<p>Corvus Pharmaceuticals, Inc.（纳斯达克代码：CRVS）获得了五家券商的 “适度买入” 平均评级。一位分析师将其评级为卖出，而四位分析师则将其评级为买入。平均目标价为 13.75 美元。最近的报告包括巴克莱将其评级设定为 “增持”，目标价为 16.00 美元，以及韦斯评级维持 “卖出” 评级。该股票开盘价为 6.93 美元，市值为 5.1635 亿美元。机构投资者持有该股票的 46.64%。Corvus 专注于开发免疫调节剂以治疗各种疾病</p>

<p>Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been assigned an average rating of &#34;Moderate Buy&#34; from the five brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $13.75.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc.（纳斯达克代码：CRVS - 获取免费报告）的股票在覆盖该股票的五家经纪公司中被评为 “适度买入”，MarketBeat Ratings 报告称。一位股票研究分析师给予该股票卖出评级，四位分析师给予该公司买入评级。在过去一年中，给予该股票评级的经纪公司平均一年目标价为 13.75 美元。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several analysts recently issued reports on CRVS shares. Wall Street Zen raised shares of Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 9th. Barclays began coverage on shares of Corvus Pharmaceuticals in a report on Monday. They set an &#34;overweight&#34; rating and a $16.00 target price on the stock. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Corvus Pharmaceuticals in a report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>几位分析师最近对 CRVS 股票发布了报告。华尔街禅在 8 月 9 日的报告中将 Corvus Pharmaceuticals 的股票评级从 “卖出” 上调至 “持有”。巴克莱在周一的报告中开始覆盖 Corvus Pharmaceuticals 的股票。他们对该股票设定了 “增持” 评级和 16.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Corvus Pharmaceuticals 股票的 “卖出（d-）” 评级。</p>
</div><p><strong>Read Our Latest Report on CRVS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CRVS 的最新报告</strong></p>
</div><h2>Corvus Pharmaceuticals Trading Down 4.4%</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 股票下跌 4.4%</h2>
</div><p>Shares of CRVS stock opened at $6.93 on Monday. The company has a market capitalization of $516.35 million, a PE ratio of -6.86 and a beta of 0.57. The firm has a fifty day simple moving average of $5.83 and a 200-day simple moving average of $4.49. Corvus Pharmaceuticals has a twelve month low of $2.54 and a twelve month high of $10.00.</p>
<div class="lb-trans"><p>CRVS 股票周一开盘价为 6.93 美元。该公司的市值为 5.1635 亿美元，市盈率为 -6.86，贝塔值为 0.57。该公司的 50 日简单移动平均线为 5.83 美元，200 日简单移动平均线为 4.49 美元。Corvus Pharmaceuticals 的 12 个月低点为 2.54 美元，12 个月高点为 10.00 美元。</p>
</div><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03. Equities research analysts predict that Corvus Pharmaceuticals will post -0.63 EPS for the current year.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（纳斯达克代码：CRVS - 获取免费报告）最近一次公布财报是在 8 月 7 日。该公司报告本季度每股收益为（0.10）美元，超出市场共识预期的（0.13）美元 0.03 美元。股票研究分析师预测 Corvus Pharmaceuticals 本年度每股收益将为 -0.63。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Shelton Wealth Management LLC acquired a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $101,000. China Universal Asset Management Co. Ltd. increased its stake in Corvus Pharmaceuticals by 20.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 15,488 shares of the company's stock valued at $62,000 after buying an additional 2,599 shares during the period. Squarepoint Ops LLC increased its stake in Corvus Pharmaceuticals by 37.0% during the 2nd quarter. Squarepoint Ops LLC now owns 138,462 shares of the company's stock valued at $554,000 after buying an additional 37,430 shares during the period. Sender Co &amp; Partners Inc. acquired a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $52,000. Finally, Perceptive Advisors LLC acquired a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $5,754,000. 46.64% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Shelton Wealth Management LLC 在第三季度收购了 Corvus Pharmaceuticals 的新头寸，价值约 101,000 美元。中国泛海资产管理有限公司在第二季度将其在 Corvus Pharmaceuticals 的持股增加了 20.2%。中国泛海资产管理有限公司现在拥有 15,488 股该公司的股票，价值 62,000 美元，此前在此期间又购买了 2,599 股。Squarepoint Ops LLC 在第二季度将其在 Corvus Pharmaceuticals 的持股增加了 37.0%。Squarepoint Ops LLC 现在拥有 138,462 股该公司的股票，价值 554,000 美元，此前在此期间又购买了 37,430 股。Sender Co &amp; Partners Inc. 在第二季度收购了 Corvus Pharmaceuticals 的新头寸，价值约 52,000 美元。最后，Perceptive Advisors LLC 在第二季度收购了 Corvus Pharmaceuticals 的新头寸，价值约 5,754,000 美元。46.64% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Corvus Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，专注于开发和商业化免疫调节剂产品候选药物，以治疗实体癌症、T 细胞淋巴瘤、自身免疫性疾病、过敏性疾病和传染病。其主要产品候选药物是 soquelitinib（CPI-818），这是一种选择性共价抑制剂，针对白细胞介素 2 诱导的 T 细胞激酶（ITK），目前正在进行多中心的 1/1b 期临床试验，以治疗外周 T 细胞淋巴瘤、实体肿瘤和特应性皮炎。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>Is the Reddit-ChatGPT Love Affair Over?</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>3 Copper Stocks Ready to Shine in the Next Metal Supercycle</li>
<li>Earnings Per Share Calculator: How to Calculate EPS</li>
<li>Microsoft 365 Premium Marks the Next Phase of AI Monetization</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Corvus Pharmaceuticals</li>
<li>5 只适合股息增长投资者的折扣机会</li>
<li>Reddit-ChatGPT 的爱情故事结束了吗？</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>3 只铜股票准备在下一个金属超级周期中大放异彩</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>Microsoft 365 Premium 标志着 AI 货币化的下一个阶段</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Corvus Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐，现在就买入，以便在更广泛的市场注意到之前... 而 Corvus Pharmaceuticals 并不在名单上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Corvus 制药公司（NASDAQ:CRVS）被分析师给予 “适度买入” 的平均推荐